Introduction
Interleukin-6 (IL-6) is a multifunctional cytokine that is produced by cells during a variety of in¯ammatory conditions in vivo (Tilg et al., 1997; Paquet and Pierard, 1995; Barton, 1997) . It stimulates activation and dierentiation of B and T lymphocytes, induces fever, and regulates acute phase protein synthesis (Houssiau and Van Snick, 1992; Seymour and Kurzrock, 1996; Rifas et al., 1999) . Because of its central role in modulating immunity, IL-6 production is normally tightly regulated. On exposure to an in¯ammatory stimulus (e.g., infectious agent, endotoxin, chemical and physical stresses), IL-6 levels transiently rise in vivo and then return to reference range on resolution of the insult (Akira and Kishimoto, 1992a; Swiergiel and Dunn, 1999; Callery et al., 1990) . Dysfunction of IL-6 turnover can lead to chronic elevations of the cytokine level and may have pathologic consequences (Horii et al., 1993) . For example, synovial¯uids from patients with rheumatoid arthritis, a chronic in¯ammatory disease, contain high levels of IL-6 (Otake et al., 1996) that may be responsible for some of the systemic abnormalities common in arthritic patients. Similarly, IL-6 has been implicated in the pathogenesis of psoriatic plaque (Skelly et al., 1994; Tseng et al., 1996) , which is an idiopathic skin disease that is histophathologically characterized by accelerated epidermal proliferation and in®ltration of in¯ammatory cells. In addition, has been shown to function as a growth factor in several human tumors, such as multiple myeloma, renal cell carcinoma, prostate cancer, Kaposi's sarcoma and colorectal cancer (Akira and Kishimoto, 1992b; Aoyagi et al., 1996; Adler et al., 1999; Aoki et al., 1999; Kinoshita et al., 1999) .
Recently, emerging evidence has demonstrated that IL-6 plays an important role in regulating apoptosis in many types of cells. In multiple myeloma, IL-6 has been shown to prevent apoptosis and induce expression of the anti-apoptotic protein Bcl-x/L (Lotem and Sachs, 1995; Schwarze and Hawley, 1995) that is associated with the malignant progression of multiple myeloma. The results of our recent study have also revealed that IL-6 inhibited transforming growth factor-beta 1 (TGF-b1)-induced apoptosis in human hepatoma cells through the phosphatidylinositol 3-kinase/Akt pathway . This ®nding indicates that a cross-communication between IL-6 and TGF-b1 in liver cells and deregulation of both factors may lead to the liver disease. Supportive of this concept, it has been shown that double transgenic mice expressing IL-6 and IL-6-receptors under the control of liver-speci®c promoters spontaneously developed nodules of hepatocellular hyperplasia and adenomas (Schirmacher et al., 1998) .
Basal cell carcinoma (BCC) is one of the most commonly encountered neoplasms in the world and is characterized as locally aggressive with little metastatic potential (Lear et al., 1998) . Ultraviolet (UV) irradiation is considered to be a major etiologic factor for the pathogenesis of BCC (Kricker et al., 1994) . Interestingly, UV irradiation can trigger the release of IL-6 and TNF-a from human epidermal keratinocytes (AvalosDiaz et al., 1999) . Cultured BCC cells stained with speci®c cytokine antibodies showed signi®cant expression of IL-6 (Yen et al., 1996) . These ®ndings suggest that IL-6 play a role in the pathogenesis of BCC. The purpose of the present study, therefore, was to investigate the eects of IL-6 overexpression on BCC cell proliferation and apoptosis regulation. Some cell regulators involved in apoptosis and angiogenesis were subsequently examined. Finally, we studied the tumorigenicity of IL-6 transfected BCC cells of nude mice.
Results

Establishment and characterization of IL-6 BCC transfectants
The human IL-6 constitutive expression plasmid, pCMV-IL-6, and the control vector, pCMV, were transfected into human BCC cells. After transfection, cells were cultured in medium containing 400 mg/ml of neomycin. Each colony that grew after G418 selection was picked and expended. We designated the BCC cells transfected with the IL-6 expression vector as BCC/IL-6 cells (BCC/IL-6, BCC/IL-6-c1 and BCC/IL-6-c2) and with vector control as BCC/neo. RT ± PCR analysis showed that two dierent clones (BCC/IL-6-c1 and BCC/IL-6-c2) and the mixture of IL-6 transfectants (BCC/IL-6) expressed more IL-6 mRNA than BCC/ neo or BCC cells (Figure 1a ). The level of GAPDH mRNA was used as an internal control. Compatibly, ELISA analysis showed that IL-6 transfected BCC clones (BCC/IL-6-c1 and c2) and mixtures (BCC/IL-6) produced higher amounts of secreted IL-6 as compared with neo and parental BCC cells (Figure 1b) . We further examined whether the level of IL-6 receptors were aected in these IL-6-overexpressing BCC cells. To address this, we quantitated the amounts of IL-6 receptor using indirect immuno¯uorescence staining and subsequent¯ow cytometric analysis using an antibody which speci®cally recognized the ligand binding subunit of IL-6 receptor, IL-6Ra. As shown in Figure 1c , the IL-6 transfectants and control cells expressed the same levels of IL-6Ra on their cellular surface.
Next, we examined the growth properties of IL-6 transfectants and the control BCC cells by determining the DNA synthesis rate. The results of the 3 Hthymidine pulse-labeling assay are shown in Figure  2a . Overexpression of IL-6 in BCC cells promoted the DNA synthesis rate, suggesting that the expression of IL-6 make BCC cells acquire the growth advantage.
To compare the cell transformation ability between IL-6 transfectants and neo control cells, we employed the soft agar growth assay to evaluate whether overexpression of IL-6 can mediate cellular transformation. Under seeding the same cell number (1610 3 ), approximately 57.3 and 7.6 colonies per dish were formed in soft agar for BCC/IL-6 and BCC/neo, respectively ( Figure 2b ). However, in the parental BCC cells only 3.2 colonies grew in soft agar for each dish (Figure 2b ). Microscopic examination also revealed that the colonies of BCC/IL-6 cells were much larger than those of BCC/neo cells (Figure 2c ). These results indicated that over-expression of IL-6 in BCC cells enhanced the cellular proliferation rate and anchorageindependent characteristics.
Expression of IL-6 in BCC cells confers resistance to apoptosis
Previous studies have shown that BCC cells will undergo apoptosis when treated with photodynamic therapy (PDT) or UVB irradiation (Brash, 1997). Here we investigated whether IL-6 overexpression modulated the sensitivity of BCC cells to apoptosis by PDT or UVB. BCC/IL-6, BCC/neo and BCC cells were pretreated with 100 ng/ml-Aminolevulinic (ALA) for 24 h followed by 400 mJ/cm 2 visible light exposure or treatment with UVB 25 mJ/cm 2 irradiation. As shown in Figure 3a , agarose gel electrophoresis analysis revealed that IL-6 transfectants displayed a remarkable resistance to UVB-triggered internucleosomal DNA fragmentation. In contrast, BCC/neo or parental BCC cells were susceptible to UVB irradiation-induced DNA fragmentation. To verify whether the antiapoptotic eect of IL-6 was limited to BCC cells, we transfected the IL-6 expressing vector, pCMV-IL-6, into human prostatic cancer PC-3 cells. Consistently, we found that IL-6 overexpressing PC-3 cells also conferred resistance to UVB-induced apoptosis ( Figure  3b ). The resistance of BCC/IL-6 cells to UVB was also observed in nuclear morphologically characteristics of apoptosis, i.e., chromatin condensation and nuclear fragmentation (Figure 3c I ± III), as demonstrated by staining with Hoechst 33258. Flow cytometry analysis of hypodiploid cells revealed that all IL-6-overexpressing BCC clones (BCC/IL-6, BCC/IL-6-c1, or BCC/IL-6-c2) were much less sensitive to PDT when compared with BCC/neo or parental BCC cells (Figure 3d ). In addition to apoptotic characteristics, Trypan blue exclusion assay con®rmed that IL-6-overexpressing BCC cells displayed more viability than the neo control or parental BCC cells (data not shown). The above results suggest that IL-6-overexpressing BCC cells exhibited a markedly anti-apoptotic eect, and that the eect was not due to an increase in cell proliferation. To clarify whether anti-apoptotic activity of these transfectants was due to the speci®c eect of the cytokine IL-6, we exposed BCC cells to various concentrations of recombinant IL-6 and examined their sensitivity to UV. Figure 3e reveals that treatment with 20 and 40 ng/ml of IL-6 resulted in 50 and 80% protection of UV-induced apoptosis, respectively, in BCC cells. This suggests that exogenous IL-6 treatment exhibited a similar cellular response to UV as compared to IL-6 transfectants.
To understand the mechanism underlying IL-6 prevented apoptosis in BCC cells, we examined the expression of the Bcl-2 family in IL-6-transfected and control BCC cells by immunoblotting. Notably, Figure  4a shows that the anti-apoptotic Mcl-1 protein was C Figure 1 Determination of IL-6 mRNA and protein levels in IL-6 transfected BCC cells (a) RT ± PCR analysis of alternative level of IL-6 mRNA in various independent IL-6-overexpressing clones such as BCC/IL-6-c1, BCC/IL-6-c2, IL-6-overexpressing mixture (BCC/IL-6), and control cells (BCC, BCC/neo). The data were presented using agarose gel. Speci®c primers for IL-6 and GAPDH were employed as described in Materials and methods. (b) ELISA analysis of the amount of secreted IL-6 for dierent IL-6-transfected BCC clones. For this assay, each clone was incubated in serum free RPMI for 24 h, and then aliquots of medium from each culture were collected to perform ELISA according to the manufacture procedure of R&D. The means (bars, s.d.) were calculated from at least there independent experiments for each sample. (c) Determination of the level of IL-6 receptor in IL-6 transfectants. The expression level of IL-6 receptor a-chain (IL-6Ra) for each transfectant was determined by using anti-IL-6 Ra antibody (R&D) and analysed with¯owcytometer as described in Materials and methods highly expressed in all three IL-6-overexpressing BCC cells, but only a low level of Mcl-1 protein was expressed in BCC/neo or parental BCC cells. However, the level of other Bcl-2 family members, including Bcl-2, Bcl-x/L, and Bax, there was no dierence between IL-6 transfectants and neo control cells. To further con®rm whether Mcl-1 plays a role in mediating the antiapoptotic activity of IL-6, experiments were designed to reduce the endogenous level of cellular Mcl-1 and examine its in¯uence on the survival of BCC cells. Initially, we found that a high transfection eciency (430%) could be achieved in BCC/IL-6 cells by using liposome transfection method (data not shown). Thus, a transient-transfection assay was conducted to investi- Figure 3 Expression of IL-6 protects BCC cells against apoptosis. (a) IL-6 overexpressing BCC cells confer resistance to UVBinduced DNA fragmentation. Cells were exposed to 25 mJ/cm 2 UVB and the cellular DNA was extracted as described in Materials and methods. The DNA laddering was analysed using 1.8 ± 2% agarose gel. (b) IL-6 transfected PC-3 prostatic cancer cells also confer resistance to UVB-induced DNA fragmentation. (c) Morphological examination of IL-6-transfected BCC and neo control cells after treatment with 25 mJ/cm 2 UVB. Neo control (BCC/neo), IL-6-transfected BCC (BCC/IL-6), and parental BCC (BCC) cells were exposed to UVB and determined their morphological changes by staining Hoechst 33258¯uorescent dye. (d) Flow cytometric analysis of hypodiploid cells induced by photodynamic therapy (PDT) individual cell lines. Each cell line was treated with 100 ng/ml-Aminolevulinic (ALA) for 24 h followed by 400 mJ/cm 2 visible light and harvested at indicated times for¯ow cytometric analysis. The data representing the two reproducible experiments. (e) Exogenous IL-6 protects UVB-induced apoptosis in BCC cells. Parental BCC cells were pre-exposed to various concentrations of IL-6 (0 ± 40 ng/ml) for 30 min and then were treated with 25 mJ/cm 2 UVB. After treatment, cells were harvested for Flow cytometric analysis. The data is the representative of two reproducible experiments gate this issue. BCC/IL-6-c1 cells were transfected with antisense mcl-1 vectors (pcDNA3-mcl-1-AS) or empty vectors (pcDNA3). Twenty-four hours after transfection, transfected cells were treated with UVB 25 mJ/cm 2 irradiation and subsequently incubated for further 12 h.
After treatment, the extent of apoptosis was determined as the number of apoptotic nucleus by staining with Hoechst 33258. As seen in Figure 4b , transfection of the antisense mcl-1 vector, but not control vector, eectively abolished the anti-apoptotic activity of IL-6. This ®nding indicates that the anti-apoptotic activity of IL-6 in BCC cells was mediated via the up-regulation of Mcl-1.
Tumor growth of IL-6-overexpressing BCC cells in nude mice IL-6 overexpression can induce the growth advantage, anchorage-independent, and anti-apoptotic properties in BCC cells. Thus, we evaluated the tumorigenicity of IL-6-overexpressing clone and neo control cells in nude mice model. Initially, 5610 5 BCC/neo or BCC/IL-6-c2 cells were subcutaneously injected into 4 ± 5 week old nude mice. Tumor growth was then examined daily and palpable tumors were measured on two perpendicular axes. Tumor volume was calculated assuming spherical growth using the standard formula. The mean tumor size in BCC/IL-6-c2 transplanted nude mice was approximately 500 000 mm 3 at day 35 after transplantation; whereas, the mean tumor volume in nude mice injected BCC/neo cells only reached 100 000 mm 3 on the same date (Figure 5a ).
Two weeks after inoculation, all of the 10 BCC/IL-6-c2 cell-inoculated mice bore large tumors, whereas only two of 10 BCC/neo-inoculated mice developed small tumors (Figure 5b ). The tumor sizes of BCC/IL-6-c2 and BCC/neo-transplanted nude mice were quite dierent. These results indicate that IL-6 not only promoted tumor growth but also enhanced the tumor incidence rate in nude mice.
Gross examination of the peripheral segments of the tumors revealed that high blood vessel densities surrounded the tumor in BCC/IL-6-c2-transplanted nude mice (data not shown). In contrast, no such phenomena were observed in BCC/neo-inoculated nude mice (data not shown). This indicates that IL-6 may have induced angiogenic factors during tumorigenic process. The hematoxylin and eosin staining of formalin ®xed tumor sections from BCC/IL-6 and BCC/neo-transplanted mice were further examined. Histopathologic examination results showed that the BCC/IL-6-derived tumors had multiple nucleoli, large nuclei, and more spindle-like morphology with anaplastic and pleiomorphic cells (Figure 5c ). In contrast, BCC/neo-derived tumors displayed more regular cell morphology (Figure 5c ).
Expression of angiogenic factors in IL-6 transfectants
The observation that IL-6 could induce angiogenesis in nude mice (data not shown) prompted us to investigate whether IL-6-transfected BCC cells expressed some angiogenic factors. To address this, we used both RT ± PCR and immunoblotting to analyse the expression of two angiogenic factors, Cox-2 and VEGF. As shown in Figure 6a , the expression of VEGF (upper panel) and Figure 4 (a) Immunoblot analysis of Mcl-1, Bcl-2, Bcl x/L and Bax proteins in dierent IL-6-expressing cell lines. Cell extracts were prepared and immunoblotting performed as described in the Materials and methods. Equal aliquots of protein extracted from BCC, BCC/neo, BCC/IL-6, BCC/IL-6-c1 and BCC/IL-6-c2 were electrophoresed, and the proteins were transferred to nitrocellulose ®lter. The nitrocellulose ®lter was probed with their speci®c antibodies as indicated. (b) Transfection with antisense mcl-1 abolished IL-6-mediated anti-apoptotic eect. BCC/IL-6-c1 were plated a density of 5610 4 onto a cover glass. BCC/IL-6-c1 cells were transfected 5 mg antisense mcl-1 vector (pcDNA3-mcl-1-AS) or control vector (pcDNA3) using TransFast TM transfection agent. Transfection was performed in triplicate. Twenty-four hours after transfection, cells were treated with 25 mJ/cm 2 UVB and determined their apoptotic morphological changes by staining Hoechst 33258. Results shown are the mean+standard deviation (s.d.) of the three independent experiments Cox-2 mRNA (lower panel) in IL-6-transfected BCC cells were higher than in neo control cells or parental cells. Again, consistent with the data on RT ± PCR, immunoblotting analysis showed that IL-6-overexpressing BCC cells expressed more abundant of VEGF and Cox-2 proteins when compared with neo and parental BCC cells (Figure 6b ).
Discussion
The results of this study demonstrate that IL-6 increases cell proliferation, anchorage independence and anti-apoptotic activity in BCC cells in vitro. In addition, when IL-6-transfected BCC cells were transplanted into nude mice, they also enhanced tumor size and incidence. Our current ®ndings are in agreement with other studies which showed that under the control of liver-speci®c promoters, coexpression of IL-6 and IL-6Ra in mice resulted in hepatic hyperplasia and adenomas (Maione et al., 1998) . Transplantation of the viral IL-6-expressing NIH3T3 cells into athymic mice caused tumor formation at injection site as well as other pathologic disorders, including hematopoiesis in the blood cells, hepatosplenomegaly and polyclonal hypergamma globulinemia (Aoki et al., 1999) . All of the observations from previous studies and ours suggests that IL-6 play a role in tumorigenesis of certain type of tumors.
However, the question of how IL-6 enhances the tumorigenic process arises. As mentioned before, this cytokine functions as a growth factor for various tumors such as myeloma, renal cell carcinoma, cervical carcinoma, AIDS Kaposi's sarcoma-derived cells, and certain T-and B-cell lymphomas (Aoki et al., 1999; Rezai et al., 1994; Okamoto et al., 1997; Lu et al., 1996) . In the present study, we also found that IL-6-overexpressing BCC cells displayed a high DNA synthesis rate and cellular proliferation. Therefore, the rapid growth of tumors in nude mice is mainly due to the high proliferative rate of IL-6-transfected BCC cells. However, the growth advantage alone is not sucient for the completion of tumorigenic process in vivo. Apoptosis or programmed cell death profoundly in¯uences a wide variety of physiological processes. The purpose of physiological cell death is to selectively remove the most heavily damaged or abnormal cells from the population. Hence, de-regulation of apoptosis has been implicated in several human diseases, ranging from cancer to autoimmunity, including AIDS and neurological disorders (Reed, 1994; Hanada and Saya, 1995; Thompson, 1995) . A related study indicated that transformation of colorectal epithelium to adenomas and carcinomas were associated with a progressive inhibition of apoptosis (Elder et al., 1996) . These ®ndings re¯ect the importance of apoptosis regulation as a potent mechanism involved in the multiple-stepped tumorigenesis. Under that premise, we demonstrated that IL-6-overexpressing BCC cells conferred a marked resistance to various apoptosis inducing agents such as UVB irradiation and PDT. The anti-apoptotic eect of IL-6 may have contributed to the anchorage-independent growth in soft agar as well as the increased incidence of tumors in our nude mice model. Many investigators have shown that when cells undergo anoikis or loss of anchorage dependence they die via apoptosis (Gniadecki et al., 1998) ; in contrast, upregulation of anti-apoptotic factors or genes could prevent cells from the anchorage independence-triggered apoptosis (Valentinis et al., 1998; Prisco et al., 1999) .
The question of how IL-6 protects cells from apoptosis is important and remains unclear. Several apoptosis regulators were examined in our study. Mcl-1, but no other Bcl-2 family members, was signi®cantly up-regulated in IL-6-expressing BCC cells. This implicates the possible role of Mcl-1 in IL-6-mediated anti-apoptotic eect. Mcl-1, a member of the Bcl-2 family, was cloned from the ML-1 human myeloblastic leukemia cell line (Reynolds et al., 1994) . The amino acid sequence of carboxyl portion of Mcl-1 is very similar to that of the Bcl-2 protein (Dietrich et al., 1997) . The intracellular distribution of Mcl-1 protein overlaps with that of Bcl-2 with a prominent mitochondrial membrane (Yang et al., 1995) , suggesting that they share the same function in regulation of apoptosis. Indeed, overexpression of Mcl-1 delays apoptosis induced by various inducing agents such as c-Myc overexpression, growth factor withdrawal, and other cytotoxic agents (Ando et al., 1998; Wang et al., 1999) . Direct evidence from transient transfection assay showing that blocking Mcl-1 expression by antisense mcl-1 could abolish the anti-apoptotic eect of IL-6 (as shown in Figure 4b ). These studies suggest an indispensable role of Mcl-1 in cell survival. This is the ®rst study to demonstrate that Mcl-1 upregulation is possibly involved in IL-6-mediated antiapoptotic eect. However, the increased expression of Mcl-1 by IL-6 is not limited to BCC cells. In human hepatoma cells, we found that IL-6 stimulation also up-regulated the Mcl-1 mRNA and protein in a transient manner (unpublished data). We have previously shown that IL-6 prevented TGF-b1-induced apoptosis mainly through PI3K/Akt pathway . Therefore, whether the signaling of the PI3K pathway is involved in IL-6-induced Mcl-1 expression remains unknown and needs further investigation.
Our in vivo data qualitatively showed that the tumors from nude mice transplanted IL-6-expressing BCC cells were more vascularized compared with controls. In line with this observation, we found that two angiogenic factors, Cox-2 and VEGF, were expressed at both mRNA and protein level in IL-6-transfected BCC cells but not in control BCC cells. Our data are in agreement with the work by Cohen et al. (1996) who have shown that IL-6 stimulated the expression of VEGF transcripts in various cell lines. When athymic mice were transplanted with viral IL-6-transfected NIH3T3 cells, the mice showed a profound angiogenesis in tumors, lymph nodes, and spleen (Aoki et al., 1999) . Tsujii et al. (1998) recently found that Cox-2-expressing human colon cancer CaCo2 cells produced elevated VEGF levels and promoted endothelial migration and tube formation. More interestingly, oncostatin, a member of IL-6 cytokine family, was found to induce angiogenic activity in human microvascular endothelial cells through up-regulation of Cox-2 genes (Vasse et al., 1999) . They also demonstrated that Cox-2 speci®c inhibitors blocked oncostatin-induced angiogenic activity. Thus, our current results together with others strongly suggest that IL-6 is not only a pro-in¯ammatory cytokine but also a pro-angiogenic factor.
It has been well established that chronic in¯amma-tory disorders are associated with a high risk of cancers (Cassell et al., 1998) . For example, the pro-in¯amma-tory cytokine TNF-a knock out mice and became resistance to carcinogen-induced skin tumors ). An initial step in UV-induced photocarcinogenesis is the formation of potentially mutagenic DNA damage in skin cells. In addition, UVB may induce changes in the expression of many genes (Tobin et al., 1998) and trigger the release of various cytokines from human keratinocytes, e.g., IL-6, TNF-a, IL-1, IL-10, and IL-12 (Kondo and Jimbow, 1998; EberleinKonig et al., 1998; Soriani et al., 1999) . These cytokines may provide the growth advantages for the initiated or mutant skin cells, which, in turn, enhance the development of skin cancer. In conclusion, the results of our studies suggest that IL-6 play a crucial role in UV-induced tumorigenesis of BCC by both suppressing apoptosis and actively enhancing angiogenesis.
Materials and methods
Cell culture and chemicals d-Aminolevulinic (ALA) was obtained from the Sigma Chemical Co. (Santa Ana, CA, USA). Human basal cell carcinomas (BCC) were established as described previously (Yen et al., 1996) . The cell line was cultured in an RPMI 1640 medium supplemented with 10% FCS.
Establishment of IL-6 transfectants
The pCMV-IL-6, a constitutive expression vector, carries 0.64 kb full-length human IL-6 cDNA under control of the CMV promoter/enhancer sequence. We transfected pCMV-IL-6 or pCMV into BCC cells using the TransFast TM transfection reagent (Promega Co., Madison, WI, USA). After 48 h , cells were trypsinized and replated in RPMI with 10% FCS and 400 mg/ml G418. G418 resistant clones were selected and expanded. The level of IL-6 and IL-6-a-chain receptors of each clone was determined using IL-6 ELISA kit (R&D Systems, Abingdon, UK) and¯owcytometry, respectively.
Transient transfection with antisense mcl-1 IL-6-overexpressing BCC cells (BCC/IL-6-c1) were plated 24 h before transfection at a density of 5610 4 cells onto a clover glass. Cells were transfected with 5 mg antisense mcl-1 plasmid (pcDNA3-mcl-1-AS) or control plasmid (pcDNA3) using TransFast TM transfection reagent (Promega Co.). Transfections was performed in triplicate. Twenty-four hours after transfection, the transfected cells were treated with 25 mJ/cm 2 UVB. After treatment, morphological changes in apoptotic cells were determined by staining with Hoechst 33258¯uorescent dye DNA extraction and electrophoresis for UVB or photodynamic therapy (PDT) induced apoptosis IL-6 transfected cells and control cells (1610 6 ) were treated with 25 mJ/cm 2 UVB for dierent periods of time, then harvested and washed twice in ice-cold PBS, resuspended in 500 ml TE (10 mM Tris-HCl pH 7.6, 1 mM EDTA pH 8.0), and lysed in 500 ml lysis buer (3% SDS, 50 mM Tris, pH 12.6) at room temperature for 10 min. DNA was extracted using phenol and chloroform before precipitation with 95% ethanol. DNA pellets were ®nally dissolved in TE buer, and treated with RNase A for 40 min prior to 2% agarose gel electrophoresis. The BCC cells and control cells were also treated with 100 ng/ml-Aminolevulinic (ALA) for 24 h followed by 400 mJ/cm 2 visible light exposure. The amount of DNA fragmentation was assessed as described above.
Flow cytometry analysis for apoptosis
At an indicated time, cells were harvested and ®xed in 75% ethanol at 7208C for at least 1 h. After centrifugation (2000 r.p.m.) for 5 min at 48C, the cell pellets were resuspended in 0.5 ml of a buer (0.5% Triton X-100/PBS and 0.05% RNase A), and incubated for 30 min. Finally, 0.5 ml propidium iodide (P.I.) solution (50 mg/ml) was added and allowed to stand on ice for 15 ± 30 min. Fluorescence emitted from the P.I.-DNA complex was quanti®ed after laser excitation of the¯uorescent dye using FACSsor¯ow cytometry (Becton-Dickinson).
Cytofluorometric measurements of IL-6 Ra expression
Cells (1610 6 ) were washed and resuspended in 100 ml PBS. For determination of IL-6Ra expression, cells were incubated for 30 min at 48C with 1 mg mouse anti-human IL-6Ra Ab, washed twice using 1 ml PBS, and further incubated for 30 min with 50 ml¯uorescein isothiocyanate-conjugated goat anti-mouse IgG F(ab)' 2 diluted 1 : 50 in phosphate-buered saline. After the second incubation, the cells were washed twice using 1 ml PBS and resuspended in 600 ml PBS. Cyto¯uorometric analysis was performed using FACScan ow cytometry (Becton Dickinson). For controls, an IgG F(ab)' 2 antibody was used. 
Reverse transcriptase-polymerase chain reaction (RT ± PCR)
RNAs from BCC transfectants were isolated using commercial kits (BIOTECX Lab. Inc.). The total RNA was subjected to ®rst-strand synthesis using oligo-dT (Pharmacia Biotec, AB, USA) and moloney murine leukemia virus reverse transcriptase (GIBCO ± BRL) at 378C for 2 h, and the reaction was stopped by incubation at 708C for 10 min. The cDNA was then diluted to a ®nal volume of 50 ml. Diluted cDNA (5 ml) was ampli®ed in the presence of 0.5 U Taq Polymerase per ml (Advanced Biotechnologies) and 25 pmol of both the sense and the anti-sense IL-6 or GADPH oligonucleotides in PCR buer (10 mM Tris pH 9, 50 mM KCl, 1.5 mM MgCl 2 , 0.01% gelatin and 0.1% Triton X-100): IL-6 sense, 5'-ATG-TAGCCGCCCCACACAGA-3'; IL-6 antisense, 5'-CATC-CATCTTTTTCAGCCAT-3'; GAPDH, sense, 5'-GAAGGT-GAAGGTCGGAGACAA-3'; GAPDH anti-sense, 5'-GCA-GAGGGGGCAGAGATGAT-3'. The reaction mixture was incubated for 5 min at 948C and then ampli®ed by 33 PCR cycles (denaturation for 1 min at 948C, annealing for 1 min at 618C, and extension for 1 min at 728C). PCR products (10 ml) were electrophoresed in a 2% agarose gel and visualized using ethidium bromide. Fragments of expected size were obtained (250 base pairs for IL-6 and 575 base pairs for GAPDH).
Immunoblotting
The cellular lysates were prepared as described previously (Kuo et al., 1998) . A 50 mg sample of each lysate was subjected for electrophoresis on 10% SDS-polyacrylamide gels and for detection of Mcl-1, Bcl-2, Bax, Bcl-x/L, VEGF and Cox-2. The samples were then electroblotted on nitrocellulose paper. After blocking, blots were incubated with anti-Mcl-1, anti-Bcl-2, anti-Bax, anti-Bcl-x/ L, anti-VEGF and anti-Cox-2 antibodies (Santa Cruz, CA, USA) in PBST for 1 h followed by two washes (15 min each) in PBST, and then incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (Amersham, USA) for 30 min. After washing, blots were incubated for 1 min with the Western blotting reagent ECL (Amersham, USA) and chemiluminescence was detected using the exposure of the ®lters to Kodak-X-Omat ®lms for 30 s to 30 min.
Colony growth in soft agar
Soft agar assays were performed as previously described (Schlag and Flentje, 1984) . Essentially, growth in soft agar was determined in 60 mm diameter dishes prepared with a lower layer of 0.7% Agar solution in RPMI with 10% FBS; then overlaid with a 0.35% agar solution, also in growth medium, in which 1610 6 cells were resuspended. Colonies were scored 60 days after preparation. (The colonies larger than 0.1 mm in diameter were scored as positive).
Tumorigenicity assay in nude mice
Nude mice were purchased from National Health Research Institute (Taipei, Taiwan), housed in a dedicated nude mouse facility with microisolator caging, and handled under a unidirectional laminar air¯ow hood. Control-transfected BCC cells (BCC/neo), and IL-6-transfected BCC cells (BCC/IL-6-c2) were trypsinized, washed with PBS, resuspended in PBS, and adjusted to a concentration of 5610 5 cells/100 ml in PBS. Then the cell suspensions were injected subcutaneously into nude mice. Tumor development was followed in individual animals (10 per group) by daily sequential caliper measurements of length (L), width (W), and depth (H). Tumor volume was calculated by the formula L6W6H60.5236. After 8 weeks the mice were killed; the tumors were removed and weighed and a segment was excised and ®xed in 10% neutral buered formalin.
